跳至主要内容
临床试验/EUCTR2011-003791-37-DK
EUCTR2011-003791-37-DK进行中(未招募)1 期

Pre-Clinical Phase 0 Microdose Study to evaluate the effect of Melphalan, Bortezomib and Dexamethasone on cellular gene-expression. - MM phase 0 protokol

Department of Haematology, Aalborg University Hospital0 个研究点目标入组 21 人开始时间: 2011年9月30日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
21

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Any patient who,
  • is set start a planned treatment for Multiple Myelomatosis (Newly diagnosed as well as relaps and refractory disease) with one of the following chemotherapy regimens: Highdose Alkeran (includes melphalan), or VEL-DEX/Velcade therapy alone (includes Bortezomib), or VEL-DEX/Dexaven therapy alone (Includes Dexaven).
  • is 18 years or older.
  • can understand and have the will to sign the informed consent.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 21
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 21

排除标准

  • Any patient who,
  • have their planned treatment cancelled immediately prior to the experiment.
  • have received treatment with biphosphonates in the week prior to the experiment.

研究者

发起方
Department of Haematology, Aalborg University Hospital

相似试验